Aprotinin is a non-specific protein inhibitor of serine proteases, while pulmonary surfactant is a complex of specific lipids, proteins, and carbohydrates, having amphiphilic properties. Both substances have an antiviral effect – aprotinin prevents proteolytic digestion of the spine, thus inhibiting the initial stage of infection. Surfactant, on the other hand, plays an important role in the first defense mechanism of the lungs, acting as a barrier. This article indicates the possibility of combining the action of aprotinin and surfactant in one drug, which may be beneficial due to the synergy of action, as well as for economic reasons for the manufacturer - both substances can be obtained from one raw material - bovine lungs.